In vivo assessment of antiretroviral therapy-associated side effects

Carregando...
Imagem de Miniatura
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2014
Título da Revista
ISSN da Revista
Título do Volume
Editora
FUNDACO OSWALDO CRUZ
Autores
Citação
MEMORIAS DO INSTITUTO OSWALDO CRUZ, v.109, n.4, p.484-487, 2014
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Antiretroviral therapy has been associated with side effects, either from the drug itself or in conjunction with the effects of human immunodeficiency virus infection. Here, we evaluated the side effects of the protease inhibitor (PI) indinavir in hamsters consuming a normal or high-fat diet. Indinavir treatment increased the hamster death rate and resulted in an increase in triglyceride, cholesterol and glucose serum levels and a reduction in anti-oxLDL auto-antibodies. The treatment led to histopathological alterations of the kidney and the heart. These results suggest that hamsters are an interesting model for the study of the side effects of antiretroviral drugs, such as PIs.
Palavras-chave
metabolic disorders, protease inhibitor, HIV
Referências
  1. Anastos K, 2007, JAIDS-J ACQ IMM DEF, V45, P34, DOI 10.1097/QAI.0b013e318042d5fe
  2. [Anonymous], J NUTR, V134, P410
  3. Bertrand J, 2009, EUR J CLIN PHARMACOL, V65, P667, DOI 10.1007/s00228-009-0660-5
  4. Boubaker K, 1998, AIDS, V12, pF249, DOI 10.1097/00002030-199818000-00003
  5. Calza L, 2008, J INFECTION, V57, P16, DOI 10.1016/j.jinf.2008.02.006
  6. Carr A, 1998, LANCET, V351, P1881, DOI 10.1016/S0140-6736(98)03391-1
  7. Cunha J, 2013, CLIN CHEM LAB MED, V51, P371
  8. Daugas E, 2005, KIDNEY INT, V67, P393, DOI 10.1111/j.1523-1755.2005.67096.x
  9. George E, 2010, AIDS, V24, P387, DOI 10.1097/QAD.0b013e3283359253
  10. Ras J, 2000, APMIS, V108, P581
  11. Ronchini KROM, 2013, INT TRENDS IMMUN, V1, P73
  12. Singh M, 2010, AM J THER, V17, pE193, DOI 10.1097/MJT.0b013e3181ad3437
  13. Soares SRC, 2009, ATHEROSCLEROSIS, V207, P368, DOI 10.1016/j.atherosclerosis.2009.04.041
  14. Ugawa T, 2002, BRIT J PHARMACOL, V135, P1572, DOI 10.1038/sj.bjp.0704595
  15. Worm SW, 2012, J INFECT DIS, V205, P535, DOI 10.1093/infdis/jir788